Development of a furosemide-containing expandable system for gastric retention

Neumann, Marco; Heimhardt, Claudia; Seidlitz, Knut; Koziolek, Mirko; Schneider, Felix; Schiller, Christiane; Hanke, Ulrike; Anschütz, Maria; Knopke, Christian; Donath, Frank; Thoma, Rudy; Brätter, Christian; Schug, Barbara; Franke, Hanshermann

doi:10.1016/j.jconrel.2021.08.026

Cited by 7 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The AUC values recorded dur-ing fed state were 10 times higher than the respective values after fasted intake of the system. Therefore, this study demonstrated not only the potential of this novel system for gastroretentive controlled-release applications, but also the value of using biorelevant test methods alongside conventional methods during the development of gastroretentive formulations [180].…”

Section: Osmotic Systemsmentioning

confidence: 83%

See 1 more Smart Citation

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

2021

View full text Add to dashboard Cite

There have been many efforts to improve oral drug bioavailability and therapeutic efficacy and patient compliance. A variety of controlled-release oral delivery systems have been developed to meet these needs. Gastroretentive drug delivery technologies have the potential to achieve retention of the dosage form in the upper gastrointestinal tract (GIT) that can be sufficient to ensure complete solubilisation of the drugs in the stomach fluids, followed by subsequent absorption in the stomach or proximal small intestine. This can be beneficial for drugs that have an “absorption window” or are absorbed to a different extent in various segments of the GIT. Therefore, gastroretentive technologies in tandem with controlled-release strategies could enhance both the therapeutic efficacy of many drugs and improve patient compliance through a reduction in dosing frequency. The paper reviews different gastroretentive drug delivery technologies and controlled-release strategies that can be combined and summarises examples of formulations currently in clinical development and commercially available gastroretentive controlled-release products. The different parameters that need to be considered and monitored during formulation development for these pharmaceutical applications are highlighted.

show abstract

Section: Osmotic Systemsmentioning

confidence: 83%

“…Neumann et al developed and characterised a novel expandable osmotic system containing furosemide as the API [180]. This system consisted of two main parts.…”

Section: Osmotic Systemsmentioning

confidence: 99%

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

2021

View full text Add to dashboard Cite

show abstract

“…It aids in reducing the dosage frequency and ultimately improves patient compliance (Arora et al, 2005;Mohapatra et al, 2020). Also, expandable dosage forms withstand stomach transit because of their bigger size than the pyloric spincture diameter (Neumann et al, 2021). Additionally, bioadhesive systems are employed to localize and adhere the delivery device within the lumen to improve absorption of the drug in site-specific manner and extend GRT O n l i n e F i r s t (Ishak, 2015).…”

Section: Drawbacks Aspectsmentioning

confidence: 99%

Assessing the potential of gastroretentive technology for gastric cancer targeting

Saini¹,

Chhabra²,

Sharma³

et al. 2022

J App Pharm Sc

View full text Add to dashboard Cite

Gastric cancer is a multifactorial disease and a major cause of mortality across the globe. Initially, gastric cancer reveals no related symptoms; therefore, patients come to the notice of the clinicians only in advanced stages. Chemotherapy, radiation, surgery, immunotherapy, etc. are some of the common treatment interventions for stomach cancer. Traditional oral chemotherapy reveals several limitations, including inadequate oral bioavailability, repeated dosage, low solubility, short gastric residence period, etc. To address these issues, unique technological advancements recognized as gastroretentive drug delivery system (GRDDS) have been explored by scientists globally. The GRDDS has acquired tremendous significance in the avenue of oral drug delivery. This is a frequently utilized and encouraging methodology of retaining the dosage form in the stomach for a prolonged time and slowly releasing the drug, which can address many of the problems associated with traditional oral delivery. The current review addresses the causes of gastric cancer, significant insights, and classification along with treatment strategies for gastric cancer. Advancements in gastroretentive technology in the treatment of stomach cancer are also focused in the present paper.

show abstract

Prolongation of the gastric residence time of caffeine after administration in fed state: Comparison of effervescent granules with an extended release tablet

Foja,

Senekowitsch,

Winter

et al. 2024

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Development of a furosemide-containing expandable system for gastric retention

Cited by 7 publications

References 40 publications

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

Assessing the potential of gastroretentive technology for gastric cancer targeting

Prolongation of the gastric residence time of caffeine after administration in fed state: Comparison of effervescent granules with an extended release tablet

Contact Info

Product

Resources

About